- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about RHHBY
Recent news which mentions RHHBY
From Benzinga
Here's Why Merck Stock Vaulted Higher in October
November 08, 2021
From Motley Fool
The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More
November 08, 2021
From Benzinga
Will Pfizer Outgun Merck With Oral COVID-19 Pill?
November 05, 2021
From Benzinga
7 European Stocks to Buy to Diversify Your Portfolio
November 04, 2021
From InvestorPlace
Novartis To Offload Its Stake Back To Roche For $20.7B
November 04, 2021
From Benzinga
Galecto To Test GB1211 Combined with Roche's Tecentriq In First Line Lung Cancer Setting
November 02, 2021
From Benzinga
2 Growth Stocks That Could Deliver 1,000% Returns
October 31, 2021
From Motley Fool
3 Beaten-Down Biotech Stocks -- Can They Recover?
October 31, 2021
From Motley Fool
How Atea's Clinical Flop Shakes Up the COVID-19 Pill Market
October 29, 2021
From Motley Fool
Should Biogen Investors Be Preparing for the Worst?
October 27, 2021
From Motley Fool
From Motley Fool
Why Atea Pharmaceuticals Stock Got Crushed This Week
October 22, 2021
From Motley Fool
Why Ionis Pharmaceuticals Stock Is Down 13% This Week
October 22, 2021
From Motley Fool
From Benzinga
7 Penny Stocks to Buy to Sidestep the Noise on Wall Street
October 21, 2021
From InvestorPlace
Are These 2 Companies Next for Short Squeezes?
October 21, 2021
From Motley Fool
From Benzinga
AstraZeneca Pulls Plug On MCL-1 Cancer Drug Trial
October 20, 2021
From Benzinga
The Daily Biotech Pulse: Novavax Retreats Amid Vaccine Issues, LumiraDx COVID Test Approved In India, Sesen Shines On Positive Bladder Cancer Review
October 20, 2021
From Benzinga
Why Atea Pharmaceuticals Is Imploding Today
October 19, 2021
From Motley Fool
David v Goliath in The Race to Develop an Oral Therapy for COVID-19
October 19, 2021
From Benzinga
From Benzinga
Why Are Atea Pharmaceuticals Shares Plunging Today?
October 19, 2021
From Benzinga
Why Infinity Pharmaceuticals Shot Nearly 4% Higher Today
October 18, 2021
From Motley Fool
Roche's Tecentriq Wins FDA Approval In Adjuvant Lung Cancer Setting
October 18, 2021
From Benzinga
The Week Ahead In Biotech (Oct. 18-23): J&J, Biogen Kickstart Big Pharma Earnings, Regeneron-Sanofi, Roche Await FDA Decisions And IPOs
October 18, 2021
From Benzinga
3 COVID-19 Pill Stocks to Watch
October 16, 2021
From Motley Fool
Why Relay Therapeutics Is Up 30% This Week
October 15, 2021
From Motley Fool
2 Penny Stocks That Could Soar Soon
October 14, 2021
From Motley Fool
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.